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Abstract
Background: The tazarotene-induced gene 1 (TIG1) is a putative tumor suppressor gene. We have recently
demonstrated both TIG1A and TIG1B isoforms inhibited cell growth and induced the expression of G protein-
coupled receptor kinase 5 (GRK5) in colon cancer cells. Because elevated prostaglandin E2 (PGE2) signaling plays a
significant role in colorectal carcinogenesis, the objective of this study was to explore the effect of TIG1 on PGE2-
induced cellular proliferation and signaling in colon cancer cells.
Methods: HCT116 cells as well as TIG1A and TIG1B stable cells established from HCT116 colon cancer cells using
the GeneSwitch system were used. TIG1 isoform expression was induced by mifepristone treatment in stable cells.
Cell growth was determined using the WST-1 cell proliferation assay. Activation of b-catenin/TCF and cyclic
adenosine monophosphate (cAMP)/CREB signaling pathways were determined using luciferase reporter assays.
Expression and subcellular distribution of b-catenin were analyzed using Western blot and confocal microscope.
Levels of cAMP were measured using an enzyme immunoassay. RNA interference was used to examine the effects
of TIG1- and GRK5-mediated changes.
Results: PGE2-stimulated cell growth was reduced in inducible TIG1A- and TIG1B-stable HCT116 cells. GRK5
expression was upregulated by both TIG1A and TIG1B isoforms, and its expression suppressed PGE2-stimulated
HCT116 cell growth. GRK5, TIG1A, and TIG1B expression significantly inhibited PGE2-stimulated b-catenin/TCF and
cAMP signaling pathway reporters and cAMP. Also, PGE2-stimulated nuclear localization of b-catenin was inhibited
by expression of TIG1A and TIG1B, which was ameliorated by both TIG1 and GRK5 siRNAs.
Conclusions: TIG1 suppressed PGE2-stimulated Wnt and cAMP signaling pathways in colon cancer cells through
GRK5.
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Background
The tazarotene-induced gene 1 (TIG1) gene, also known
as retinoic acid receptor responder 1 (RARRES1) gene
[1], may be a tumor suppressor [2,3]. Its expression is
frequently downregulated through promoter hyper-
methylation in various carcinomas [3-10]. Ectopic
expression of the TIG1A and TIG1B isoforms suppress
cellular growth and/or invasion of cancer cells [2,3,5,11].
TIG1 is differentially expressed in spontaneously regres-
sing melanoma [12] and related to cellular differentia-
tion of mesenchymal stem cells [13] and colorectal
carcinomas [14]. TIG1 is a carboxypeptidase inhibitor
for ATP/GTP binding protein-like 2 (AGBL2) [15].
Prostaglandin E2 (PGE2), which is regulated by
cyclooxygenase-2 (COX-2), promotes the growth and
invasion of colorectal tumors [16]. PGE2 receptors,
which are G protein-coupled receptors (GPCRs), consist
of four subtypes, namely EP1-4 [17]. Signaling through
EP2 activates the protein kinase A (PKA) pathway that
results in phosphorylation of cyclic adenosine monopho-
sphate (cAMP) response element binding protein
(CREB) [17]. The Wnt signaling pathway, which is acti-
vated in most colorectal cancer cells and some precan-
cerous lesions, is also activated by PGE2 [18,19]. PGE2-
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in nuclear b-catenin accumulation and transcription fac-
tor 7 (TCF7)-mediated transcription [19-22].
G protein-coupled receptor kinases (GRKs) inhibits
GPCR signaling through phosphorylation-dependent
[23] and -independent mechanisms [24]. The GRK
family is comprised of seven members with various tis-
sues distributions. GRK-2, -3, -5, and -6 are expressed
ubiquitously [25]. GRKs also bind directly to non-GPCR
complexes, such as p38 mitogen-activated protein
kinases [26], IB [27], and p53 [28].
The TIG1A isoform (NP_996846.1) shares the N-
terminal 224 amino acids with TIG1B, (NP_002879.2).
Expression of both TIG1A and TIG1B isoforms upregu-
lated GRK5 expression and inhibited the growth of
HCT116 and SW620 colon cancer cells [11]. GRK5
plays an important role in the TIG1-mediated growth
inhibition, since knockdown GRK5 expression signifi-
cantly alleviated TIG1A-induced growth suppression.
PGE2 plays pivotal roles in colorectal carcinogenesis,
possibly related activation of the Wnt signaling pathway
through the increased nuclear b-catenin [19]. However,
whether GRK5 regulates PGE2-mediated growth stimu-
lation has yet to be determined. The objective of the
present study was to determine the effects of TIG1
expression on PGE2-mediated cell growth and the b-
catenin/TCF and cAMP/CREB signaling pathways, and
to investigate the possible role of GRK5 in TIG1-
mediated suppressive effects.
Methods
Construction of expression vectors
Constitutive expression vectors that encoded myc-
tagged TIG1A (pTIG1A-myc) or TIG1B (pTIG1B-myc)
fusion proteins have been described previously [11].
Constitutive expression vectors encoding a myc-tagged
GRK5 (pGRK5-myc) fusion protein was constructed as
follows. The GRK5 cDNA fragment was amplified from
human HeLa Tet-off (HtTA) cervical cancer cells,
obtained from Dr. T.-C. Chang (Department of Bio-
chemistry, National Defense Medical Center, Taiwan)
using GRK5-specific primers (sense 5’-TCGAATTC-
CATGGAGCTGGAAAACATCGTG-3’ and antisense
5’-CGGGATCCGCTGCTTCCGGTGGAG-3’). cDNAs
were digested with EcoRI and BamHI and subcloned in-
frame into the pcDNA3.1-myc-his A expression vector
(Invitrogen, Carlsbad, CA, USA).
Cell culture and transfection
HCT116 colon cancer cells (Food Industry Research and
Development Institute) were maintained in growth med-
ium consisting of McCoy’s 5A medium (BioWest,
Nuaille, France) supplemented with 25 mM HEPES, 26
mM NaHCO3, 2 mM L-glutamine, 100 units/mL peni-
cillin, 100 μg/mL streptomycin, and 10% fetal bovine
serum (Hyclone, Logan, Utah, USA) at 37°C and 5%
CO2.
HCT116 or stable cells in six-well plates were trans-
fected with the constitutive expression plasmids
described in Wu et al [11] and small interfering RNAs
(siRNAs). Plasmids (250 ng of expression plasmid, 250
ng of reporter plasmid, and 30 nM siRNA) and Lipofec-
tamine (GIBCO BRL, Gaithersburg, MD, USA) were
diluted in Opti-MEM medium (GIBCO BRL). The
DNA/Lipofectamine complexes were added to cells and
incubated for 2.5 h at 37°C. The cells were refreshed
with complete medium and were incubated for 24 h at
37°C for further analysis.
RNA interference
Three TIG1 siRNAs (Ambion, Austin, TX, USA), which
targeted both TIG1A and TIG1B, were synthesized and
targeted the nucleotides 488 to 508, 540 to 560, and 596
to 616, based on Genbank accession NM_206963. GRK5
siRNAs were targeted to nucleotides 452 to 472, 2158 to
2178, and 2406 to 2426 according to Genbank accession
NM_005308. The Silencer® negative control #1 siRNA
(Ambion) was used as a negative control. Inducible
TIG1A or control stable HCT116 cells were cultured for
24 h in 6-well plates prior to transfection.
Inducible TIG1 stable clones
Inducible TIG1A, TIG1B, and control stable clones were
established from HCT116 cells using the GeneSwitch
system [29] with minor modification as described pre-
viously [11]. TIG1A and TIG1B, expressed as V5-tagged
recombinant proteins, in stable cells were induced fol-
lowed by exposure to the synthetic progestin mifepris-
tone (MFP). MFP actives the recombinant regulatory
protein, which contains a DNA binding domain from
the yeast GAL4 protein, a ligand binding domain from
the progesterone receptor, and an activation domain
from the NF-B protein [30]. Stable clones were main-
tained in growth medium containing hygromycin and
zeocin and switched to medium without hygromycin
and zeocin overnight prior to incubation with MFP.
Cellular proliferation analysis
Control and TIG1-inducible HCT116 cells (2 × 104)
were seeded overnight and then washed twice with
phosphate buffered saline (PBS, 3.2 mM Na2HPO4, 0.5
mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, pH 7.4).
Cells were incubated with serum-free medium for 16 h,
and then cultured in serum-free medium containing
MFP (5 nM) or ethanol (0.1%) vehicle alone or in com-
bination with or without PGE2 (10 nM) for 48 h. WST-
1 reagent (100 μL; Roche, Germany) was added for 4 h
at 37°C. Absorbance at 450 and 650 nm was recorded.
The percentage of cell growth relative to control cells
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was defined as [(A450-A650) of MFP or PGE2-treated
cells/(A450-A650) of vehicle cells] × 100%. All experi-
ments were performed in triplicate.
To investigate the effects of GRK5 on PGE2-stimu-
lated cell growth, HCT116 cells were plated overnight
and then transfected with 150 ng of GRK5 or control
expression vector for 24 h. Cells were washed twice
with PBS, incubated in serum-free growth medium for
16 h and then cultured in the absence or presence of 10
nM PGE2 for 48 h. Cell proliferation was measured
using the WST-1 reagent as described above.
Western blot analysis
Total cytosol extracts were prepared in lysis buffer (25
mM HEPES, pH 7.5, 150 mM NaCl, 1% Igepal CA-630,
10 mM MgCl2, 1 mM EDTA, and 10% glycerol) contain-
ing 20 μg/mL aprotinin and 20 μg/mL phenylmethylsul-
fonyl fluoride and 2 mM NaF and 1 mM Na3VO4.
Proteins (5 to 100 μg) were separated using 10-12% poly-
acrylamide gels containing sodium dodecyl sulfate and
were then transferred to polyvinylidene difluoride mem-
branes. After blocking, the membranes were incubated
with anti-V5 (Invitrogen), anti-myc (Invitrogen), anti-
GRK5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
anti-b-catenin (Sigma, Saint Louis, MO, USA), anti-lamin
B1 (Invitrogen), anti-glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH; Cell Signaling Technology, Beverly,
MA, USA), or anti-actin (Sigma) antibodies for 12 h at 4°
C. The appropriate horseradish peroxidase-conjugated
secondary antibodies (Calbiochem, Darmstadt, Germany)
was then added at room temperature for 1 h. Specific
protein bands were developed using the Amersham ECL
(Amersham, Bucks, UK). Relative protein expression was
quantified following normalization to the housekeeping
gene protein levels.
Nuclear and cytoplasmic fractionation
To determine the nuclear or cytosolic distribution of b-
catenin, cell fractionation was performed using the
Qproteome cell compartment kit (Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions with
the addition of protease and phosphatase inhibitors to
all buffers. Nuclear (10 μg) and cytosolic (25 μg) extracts
were analyzed using Western blot analysis. Cytosolic b-
catenin levels were first normalized to GAPDH levels,
and nuclear b-catenin levels were normalized to lamin
B1 levels. Cytosolic b-catenin was then normalized to
cytosolic b-catenin protein levels in the respective cells
or control stable cells without PGE2 treatment. Simi-
larly, nuclear b-catenin levels were then normalized to
nuclear b-catenin protein levels in the respective cells or
control stable cells without PGE2 treatment for the
siRNA study. Finally, relative levels of nuclear b-catenin
relative to that of cytosolic b-catenin were calculated,
and the level of nuclear b-catenin in the respective cells
or in control stable cells without PGE2-treatment was
designated as 1.0.
Luciferase reporter assay
TOPFLASH (Upstate Biotechnology, Lake Placid, NY,
USA) and CREB reporter (pCREB-Luc; Stratagene, La
Jolla, CA, USA) activities were assessed in transiently
transfected HCT116 cells. HCT116 cells (1 × 105) were
plated in six-well plates in growth medium for 24 h.
After transient transfection with 500 ng plasmids, the
cells were serum starved for 16 h and stimulated with
10 nM PGE2 for 24 h at 37°C. Alternatively, inducible
TIG1A, TIG1B, or control stable cells were plated over-
night, transfected with 500 ng reporter plasmid, incu-
bated with 5 nM MFP for 24 h, serum starved for 16 h,
and incubated with PGE2 (10 nM) for 24 h. To analyze
the effect of GRK5 or TIG1 knockdown on reporter
activity, inducible or control stable cells were cotrans-
fected with siRNAs and reporter plasmids followed by
serum starvation and then stimulation with 5 nM MFP
for 24 h. MFP was present during the subsequent serum
starvation and PGE2 treatment.
Cells were harvested in reporter lysis buffer (Promega,
Madison, WI, USA). Luciferase activity was measured
using the luciferase assay kit (Stratagene) and a multi-
functional microplate reader (Infinite F200, Tecon, Dur-
ham, NC, USA). Relative luciferase activity of each sam-
ple was determined after normalizing for the protein
concentration of each lysate. All experiments were per-
formed in triplicate.
Confocal and immunofluorescent analysis
Stable cells (1 × 105) were plated on poly-L-lysine-
coated coverslips in 35-mm dishes in growth medium.
Cells were treated with 5 nM MFP for 24 h, maintained
in serum-free medium for 16 h, treated with 10 nM
PGE2 for 30 min, washed twice with PBS, and fixed
with 4% paraformaldehyde. Alternatively, cells were
transfected with siRNAs prior to MFP treatment, serum
starvation, and PGE2 treatment. MFP was present dur-
ing the serum starvation and PGE2 treatment. Cells
were permeabilized in 0.1% Triton X-100/PBS for 15
min. After washing, cells were blocked in PBS contain-
ing 2% bovine serum albumin for 1 h at room tempera-
ture, incubated with anti-b-catenin antibody at 37°C for
2 h followed by the Alexa Fluor@ 488 goat anti-mouse
IgG for 1 h at room temperature, stained with 1 μg/mL
4’6-diamidino-2-phenylindole (DAPI), and analyzed with
a laser scanning confocal microscope (Leica TCS SP5
scanner, Leica, Bensheim, Germany). Percentage of cells
expressing nuclear b-catenin was determined by ran-
domly analyzing 250 to 300 cells from each treatment
group.
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Measurement of cAMP levels
Cells were cultured onto 6-well plates overnight and
then incubated with 5 nM MFP in complete medium
for 24 h. After washing twice with PBS, cells were
serum starved for 16 h and then incubated in the
absence or presence of 10 nM PGE2 for 5 min. Cells
were lysed with 0. 1 N HCl for 20 min, scraped, col-
lected by centrifugation. Levels of cAMP in the superna-
tants were determined using a cyclic AMP EIA kit
(Cayman Chemical, Ann Arbor, MI, USA) according the
manufacturer’s instructions.
Statistical analysis
Numerical data are shown as mean ± standard deviation
(SD) of triplicates from each independent experiment.
Cell proliferation and luciferase activities were analyzed
using the student’s t-test. P-values less than 0.05 were
considered statistically significant.
Results
TIG1A and TIG1B upregulate GRK5 expression and
suppress PGE2-stimulated HCT116 cell growth
In the COX-2-negative HCT116 cells, TIG1A and
TIG1B expression was markedly induced after the
respective stable cells were incubated with 5 nM MFP
for 24 and 48 h (Figure 1A). GRK5 expression was evi-
dently increased in both TIG1A and TIG1B stable cells
exposed to 5 nM MFP for 24 to 48 h. No basal TIG1A,
TIG1B and GRK5 expression was detected in MFP-trea-
ted control stable cells as well as TIG1A and TIG1B
stable cells in the absence of MFP treatment. In addi-
tion, the expression of b-catenin was not altered. “Stable
TIG1A- or TIG1B-expressing cells” were used to denote
inducible TIG1A or TIG1B cells exposed to MFP (5
nM) treatment thereafter.
In control HCT116 stable cells, PGE2 (10 nM) treat-
ment for 48 h significantly stimulated cell proliferation,
and the effect was not altered by co-incubation with 5
nM MFP (Figure 1B). However, levels of PGE2-stimu-
lated growth in stable TIG1A- and TIG1B-expressing
cells were significantly suppressed (Figure 1C). There-
fore, MFP induced TIG1A, TIG1B and GRK5 expression
in the inducible HCT116 stable cells. Also, PGE2-stimu-
lated growth was significantly suppressed by induced
expression of TIG1A and TIG1B. A similar inhibition of
PGE2-stimulated growth was also demonstrated in indu-
cible TIG1A, TIG1B and control stable cells established
from COX-2-positive SW620 colon cancer cells [11,31]
(additional file 1).
TIG1 suppressed PGE2-stimulated TOPFLASH and CREB
reporter activities and b-catenin nuclear localization
TOPFLASH and CREB reporter assays were first used to
investigate the effects of TIG1 expression on PGE2-
stimulated Wnt and PKA signaling pathways by measur-
ing b-catenin/TCF- and cAMP/CREB-mediated reporter
activities, respectively. PGE2 treatment significantly sti-
mulated TOPFLASH and CREB reporter activities in
control HCT116 stable cells (Figure 2A). However, in
stable TIG1A- and TIG1B-expressing cells, PGE2-stimu-
lated TOPFLASH reporter activity was significantly
decreased, and PGE2-stimulated CREB reporter activity
was significantly suppressed in TIG1A-expressing cells.
The effects of TIG1 on PGE2-stimulated b-catenin
nuclear localization in HCT116 cells were then
Figure 1 Effects of TIG1A and TIG1B expression on PGE2-
stimulated HCT116 cell proliferation. (A) Western blot analysis of
TIG1A, TIG1B, GRK5 and b-catenin expression in MFP (5 nM)-induced
TIG1 and control (Ctrl) stable clones. (B) Effect of MFP on PGE2-
stimulated growth of control stable cells. (C) Effects of TIG1A and
TIG1B expression on PGE2-induced HCT116 cell growth.
Representative results of three independent experiments are shown.
*, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 2 Effects of TIG1A and TIG1B expression on b-catenin/TCF- and CREB-mediated activities and b-catenin subcellular localization
on TIG1A- and TIG1B-expressing HCT116 cells. (A) b-catenin/TCF (top panel)- and CREB (bottom panel)-mediated activities were analyzed
using luciferase reporters. Indicated stable cells were transfected with the reporter plasmid and then incubated with 5 nM MFP for 24 h, serum
starved for 16 h, and then treated with or without PGE2 (10 nM) for 24 h. MFP was present during serum starvation and PGE2 treatment in all
similar experiments. Cellular lysates were analyzed for transactivation activity of the TOPFLASH or CREB luciferase reporters. Results were
expressed as means ± SD from triplicate samples after normalization to protein concentration and then to the results obtained from TIG1A-
inducible cells without PGE2 treatment. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (B) Effects of TIG1 isoforms on b-catenin subcellular distribution
were determined by subcellular fractionation and Western blot analysis. Indicated stable cells were incubated with 5 nM MFP for 24 h, serum
starved for 16 h, and incubated with or without 10 nM PGE2 for 30 min. After subcellular fractionation, b-catenin, TIG1A, TIG1B, lamin B1, and
GAPDH levels were determined by Western blot analysis. Normalization of nuclear (N) and cytosolic (C) b-catenin levels was described in the
Materials and Methods section, and the respective cells without PGE2-treatment were designated as 1.0. (C) Effects of TIG1 isoform expression on
b-catenin subcellular distribution was determined by immunofluorescent analysis. Stable cells were incubated with MFP, serum starved, and
incubated with PGE2 for 30 min as described above. b-catenin localization (green) and nuclei (blue) were analyzed using a laser scanning
confocal microscope. Bars, 10 μm. Arrows indicate nuclear b-catenin.
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determined by Western blot analysis of cytosolic and
nuclear extracts. After exposure to 10 nM PGE2 for 5
min to 1 h, the greatest nuclear b-catenin accumulation
as determined by immunofluorescent analysis was evi-
dent at 30 min in control stable cells (data not shown).
The majority of TIG1 isoforms were detected in the
cytosolic fractions (Figure 2B). Levels of nuclear b-cate-
nin in MFP-treated control stable cells were increased
to 1.2-fold followed by exposure to PGE2 (10 nM) for
30 min. However, PGE2 did not stimulate nuclear b-
catenin accumulation in both TIG1A- and TIG1B-
expressing cells. Similar results were obtained using
immunofluorescent staining of b-catenin in response to
PGE2 stimulation in MFP-treated stable cells (Figure
2C). In control HCT116 stable cells, nuclear b-catenin
was detected in 5.4% of vehicle-treated cells (data not
shown), which increased to 31.5% upon PGE2 stimula-
tion (top panel). However, PGE2 treatment of stable
TIG1A- and TIG1B-expressing cells resulted in nuclear
b-catenin detected in only 8.7 and 11.0% of cells, respec-
tively. In addition, the intensity of nuclear b-catenin
staining in PGE2-stimulated TIG1A and TIG1B expres-
sing cells was much weaker than that observed in
PGE2-and MFP-treated control stable cells.
Thus, upon induced expression of both TIG1A and
TIG1B, suppression of both PGE2-stimulated TOP-
FLASH reporter activities and nuclear b-catenin locali-
zation in MFP-treated stable HCT116 cells was
observed. PGE2-stimulated CREB reporter activities
were also suppressed by TIG1B, but to a lesser extent.
Effects of GRK5 expression on PGE2-stimulated cell
growth and TOPFLASH and CREB reporter activities
To investigate the effects of GRK5 on PGE2-mediated
signal pathways, GRK5 expression vector was con-
structed. Expression of the GRK5 fusion protein with
an expected molecular weight of 67 kDa was observed
in HCT116 cells (Figure 3A). In vector control-trans-
fected cells, PGE2 significantly increased TOPFLASH
and CREB reporter activities by 3.1- and 2.5-fold,
respectively (Figure 3B), which was not observed in
GRK5-expressing HCT116 cells. PGE2-stimulated
TOPFLASH and CREB reporter activities were signifi-
cantly suppressed by 77.4 and 84.4% in GRK5-expres-
sing cells treated with PGE2 (Figure 3B). Because
PGE2 stimulates TOPFLASH and CREB reporter activ-
ities through the PGE2 receptor subtype 2, EP2, in
DLD-1 colon cancer cells [19], the effects of GRK5
expression on PGE2-stimulated TOPFLASH and CREB
reporter activities in EP2-transfected HCT116 cells
were analyzed. GRK5 suppressed both reporter activ-
ities in a dose-dependent manner (additional file 2).
Finally, PGE2 treatment for 2 days significantly
increased cell growth by 25% in control transfected
cells, which was significantly decreased to 11.9% upon
GRK5 expression (Figure 3C). Results from transiently
transfected HCT116 cells demonstrated that GRK5
suppressed PGE2-stimulated growth as well as TOP-
FLASH and CREB reporter activities. Also, GRK5
Figure 3 Effects of GRK5 expression on PGE2-mediated
TOPFLASH and CREB reporter activities and cell growth. (A)
HCT116 cells were transfected with control or GRK5 expression
vector for 24 h, and expression of the GRK5 fusion protein was
determined by Western blot analysis using anti-myc or anti-GRK5
antibodies. Actin expression was used as a loading control. (B)
TOPFLASH and CREB reporter activities were determined in HCT116
cells after transient expression of indicated expression vectors for 24
h, serum starvation for 16 h and then PGE2 (10 nM) incubation for
24 h. (C) Cell proliferation was determined in HCT116 cells
transfected with control or GRK5 expression vector for 24 h, serum
starvation for 16 h, and PGE2 stimulation for 48 h. Representative
results from triplicate samples were expressed as means ± SD. *, P <
0.05; **, P < 0.01; ***, P < 0.001. Control, Ctrl.
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suppressed PGE2-stimulated activation of TOPFLASH
and CREB reporters in EP2-transfected cells.
Effects of TIG1 and GRK5 siRNAs on suppression of PGE2-
stimulated TOPFLASH reporter activity and b-catenin
nuclear localization
As shown in Figure 4A, expression of TIG1A and GRK5
was completely suppressed when cotransfected with the
respective siRNAs but not the control siRNA. Cotrans-
fection of TIG1A or GRK5 expression vector with con-
trol siRNA significantly suppressed PGE2-stimulated
TOPFLASH reporter activity by 77.1 and 87.5%, respec-
tively (Figure 4B, top panel), which was completely
recovered when TIG1A-transfected cells were cotrans-
fected with TIG1 or GRK5 siRNAs. Although both
TIG1 and GRK5 siRNAs reduced TIG1-mediated sup-
pression of TOPFLASH reporter activity, only GRK5
siRNAs partially alleviated GRK5-mediated suppression
of the reporter activity. PGE2-stimulated CREB reporter
activity was significantly suppressed by 37.3 and 75.5%
upon transient transfection of TIG1A and GRK5 expres-
sion vector, respectively, which was significantly alle-
viated when cotransfected with GRK5, but not TIG1
siRNAs (Figure 4B, bottom panel).
Similar experiments in stable TIG1A expressing cells
revealed a partial knockdown of TIG1A (65.1%) and
GRK5 (50%) protein expression using the respective siR-
NAs (Figure 4C). Levels of PGE2-stimulated TOP-
FLASH and CREB reporter activities in control siRNA-
transfected TIG1A-expressing cells were significantly
lower than that of control stable cells (Figure 4D). In
stable TIG1A-expressing cells transfected with control
siRNA, PGE2 only weakly increased the TOPFLASH
and CREB reporter activities. Further, significantly
enhanced TOPFLASH and CREB transactivation, ran-
ging from 179 to 271%, was observed upon transfection
with TIG1 or GRK5 siRNAs.
The effects of GRK5 and TIG1 knockdown on PGE2-
stimulated b-catenin nuclear localization were evaluated
in MFP-treated stable cells. In MFP-treated control
stable cells transfected with control siRNA, levels of
nuclear b-catenin were designated as 1.0-fold in the
absence of PGE2 treatment; treatment with 10 nM
PGE2 for 30 min increased nuclear b-catenin to 1.4-fold
(Figure 4E). In stable TIG1A-expressing cells transfected
with control siRNA and treated with PGE2, nuclear b-
catenin decreased to 0.6-fold. Upon transfection with
siRNA specific for TIG1 or GRK5, nuclear b-catenin
increased to 1.2- and 1.0-fold, respectively. Confocal
microscopic analysis also confirmed that both TIG1 and
GRK5 siRNAs alleviated the suppression of PGE2-stimu-
lated nuclear b-catenin in TIG1A-expressing cells (addi-
tional file 3). Basal levels of nuclear b-catenin in
TIG1A-expressing cells were analyzed in TIG1A-
expressing cells transfected with control siRNA and
then incubated with or without 10 nM PGE2 for 30
min. In contrast to the increase in PGE2-stimulated
nuclear b-catenin observed in control stable cells trans-
fected with control siRNA, PGE2 treatment did not
increase nuclear b-catenin in control siRNA transfected
TIG1A-expressing cells (additional file 4).
Using siRNA, TIG1A-mediated suppression of TOP-
FLASH reporter activity and nuclear b-catenin localiza-
tion was alleviated by both TIG1 and GRK5 siRNAs,
whereas GRK5-mediated suppression of TOPFLASH
reporter activity was reversed by GRK5, but not TIG1
siRNA. Similar, but less potent, effects were observed
for CREB reporter activity.
Effects of TIG1 on cAMP levels
The effects of TIG1 on PGE2-stimulated cAMP/PKA
signaling were analyzed by measuring the levels of
cAMP. PGE2 stimulation for 5 min significantly
increased cAMP levels in control stable HCT116 cells,
but not in TIG1A- or TIG1B-expressing cells. Levels of
PGE2-stimulated cAMP were significantly decreased by
52.2 and 42.8% in TIG1A- and TIG1B-expressing cells,
respectively (Figure 5).
Discussion
The TIG1A and TIG1B isoforms exhibit growth inhibi-
tory activities on several cancer cells, including HCT116
and SW620 colon cancer cells [2,3,5,11]. The growth
suppressive activities of TIG1 may be related to the reg-
ulation of cellular apoptosis and cell cycle progression.
This is supported by our recent observation of increased
lactate dehydrogenase release in TIG1B-transfected
HCT116 cells, differential expression of apoptosis-
related genes in TIG1A- and TIG1B-expressing cells,
and delayed S phase progression in stable TIG1A-
expressing HCT116 cells [11]. The effects of TIG1 on
the regulation of cell cycle are further supported by the
regulation of tubulin phosphorylation cycles through
inhibiting the activity of carboxypeptidase AGBL2 [15].
The present study further demonstrates that both TIG1
isoforms inhibited PGE2-stimulated growth, TOPFLASH
and CREB reporter activities, cAMP levels and b-catenin
nuclear translocation.
PGE2 promotes cell growth and angiogenesis, through
activation of EP GPCRs [16]. In DLD-1 and LS174T
colon cancer cells, activation of the EP2 receptor by
PGE2 promotes the release of glycogen synthase kinase
3b (GSK-3b) from the adenomatous polyposis coli
(APC)/Axin/b-catenin complex [19]. PGE2 also
increases GSK-3b phosphorylation through PI3K/AKT
[19] and protein kinase A signaling [22]. Subsequent
suppression of b-catenin degradation results in increased
nuclear b-catenin accumulation and expression of genes
Tsai et al. Journal of Biomedical Science 2011, 18:88
http://www.jbiomedsci.com/content/18/1/88
Page 7 of 12
Figure 4 Effects of TIG1 and GRK5 siRNAs on TIG1-mediated suppression of reporter activities and nuclear b-catenin accumulation. (A)
Western blot analysis of HCT116 cell lysates transiently transfected with constitutive TIG1A or GRK5 expression vectors along with the indicated
siRNAs for 48 h using anti-myc antibodies. b-actin expression was determined as a loading control. (B) Effects of TIG1 and GRK5 knockdown on
PGE2-stimulated TOPFLASH and CREB reporter activities in transiently transfected HCT116 cells. Cells were cotransfected with indicated TIG1A,
GRK5 or control expression vector, reporter plasmid and siRNA for 24 h, serum starved for 16 h, and then incubated with 10 nM PGE2 for 24 h.
TOPFLASH (top panel) and CREB (bottom panel) reporter activities were determined. Representative results from triplicate samples were
expressed as means ± SD. (C) Effects of TIG1 and GRK5 siRNAs on TIG1A and GRK5 expression in stable TIG1A-expressing cells. Cells were
transfected with the indicated siRNAs and then incubated with or without 5 nM MFP immediately after transfection for 24 h. Expression of TIG1A
and GRK5 was determined by Western blot analysis using anti-V5 and anti-GRK5 antibodies, respectively. (D) Effects of TIG1A or GRK5 knockdown
on PGE2-stimulated TOPFLASH and CREB reporter activities in stable control and TIG1A expressing cells. Cells were transfected with the indicated
siRNAs and then incubated with 5 nM MFP for 24 h, serum starved for 16 h, and stimulated with or without 10 nM PGE2 for 24 h. MFP was
present during serum starvation and PGE2 treatment. TOPFLASH (top panel) and CREB (bottom panel) reporter activities were analyzed. (E)
Effects of TIG1 and GRK5 siRNAs on TIG1A-mediated suppression of PGE2-stimulated nuclear b-catenin accumulation in stable TIG1A-expressing
cells. Control and TIG1A stable cells were transfected with the indicated siRNA and then incubated with 5 nM MFP for 24 h, serum starved for
16 h, and treated with or without 10 nM PGE2 for 30 min. MFP was present during serum starvation and PGE2 treatment. Nuclear and cytosolic
fractions were prepared, and subcellular distribution of nuclear and cytosolic b-catenin was determined by Western blot analysis. Normalization
in the levels of nuclear and cytosolic b-catenin was described in the Materials and Methods, and the relative levels of nuclear b-catenin in
control stable cells without PGE2-treatment was designated as 1.0. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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associated with cell growth and invasion, such as cyclin
D1 and vascular endothelial growth factor.
HCT116 cells harbor a somatic b-catenin mutation
[32]; the serine deletion mutation renders it resistant to
GSK-3b-induced degradation [33], which is consistent
with the high levels of cytoplasmic b-catenin observed
before and after PGE2 treatment in the present study.
However, the significance of b-catenin mutations in col-
orectal carcinogenesis remains to be fully elucidated; no
differences in growth rate or in vitro anchorage-inde-
pendent growth have been observed [34]. Regardless,
increased nuclear b-catenin accumulation and subse-
quent TOPFLASH reporter activity following PGE2
treatment was observed in the present study, suggesting
that PGE2 induced b-catenin transactivation rather than
inhibited its degradation in HCT116 cells. Thus, TIG1
isoforms might suppress PGE2-stimulated cell prolifera-
tion through inhibition of the b-catenin/TCF transacti-
vation. Alternatively, because TIG1 isoforms also
suppressed PGE2-induced cAMP levels and cAMP/
CREB reporter activities, they might directly or indir-
ectly affect the PGE2 receptor or downstream signaling
pathways that lead to growth inhibition [35]. Since both
intracellular signaling pathways were inhibited by TIG1,
the mechanism by which TIG1 inhibited PGE2-stimu-
lated growth is therefore likely to take place at the level
involving EP receptor activation.
Studies analyzing the effect of GRKs on EP receptor
activation or PGE2-stimulated activities are limited.
GRK2, GRK3, and GRK5 mediate PGE2-stimulated
phosphorylation and desensitization of EP4 [36]. GRK5
downregulates ligand-induced GPCR signaling through
internalization [37]. Our previous study demonstrated
an important role of GRK5 in TIG1A-mediated growth
inhibition of stable TIG1A-expressing cells [11]. This
study further demonstrated that PGE2-stimulated TOP-
FLASH and CREB reporter activities were downregu-
lated by TIG1, and the effects were alleviated by GRK5
siRNA. Therefore, TIG1 may increase GRK5 expression,
which subsequently desensitizes the PGE2 receptor
through receptor phosphorylation, thereby downregulat-
ing b-catenin/TCF/TOFFLASH- and CREB-mediated
transactivation. EP2 has been shown to mediate PGE2-
stimulated b-catenin/TCF and cAMP/CREB pathways
[19]. Through transient transfection, this study demon-
strated that GRK5 dose-dependently suppressed PGE2-
stimulated TOPFLASH and CREB reporter activities in
EP2-transfected HCT116 (additional file 2) and DLD-1
(data not shown) cells. Therefore, EP2 may be one of
the targeted receptor desensitized by GRK5. We were
unable to detect endogenous EP2 expression using Wes-
tern blot analysis. Whether the TIG1-induced and
GRK5-mediated inhibition of PGE2-stimulated signaling
in HCT116 cells is mediated through EP2 or other
receptors remains to be elucidated.
GRK5 also functions through non-GPCR pathways,
phosphorylating the low density lipoprotein receptor-
related protein 6 (LRP6) and stimulating Wnt/LRP6 sig-
naling [38]. Therefore, the observed inhibitory effects of
GRK5 on PGE2-stimulated reporter activities may repre-
sent the net result after balancing the stimulatory signal
induced by GRK5 on LRP6 phosphorylation. Also,
GRK5 binds and regulates p53 [28] and IBa [27];
whether they play a role in GRK5- and TIG1-mediated
inhibition of PGE2-stimulated activities merits further
investigation. Results shown in this and our recent study
[11] have demonstrated that GRK5, TIG1A, or TIG1B
alone exhibited growth-suppressive activities. The varia-
tion in the levels of GRK5 and the extent of inhibition
in PGE2-stimulated growth between TIG1A- and TIG1-
B expressing cells was much less than the difference in
levels of MFP-stimulated TIG1A and TIG1B protein
expression HCT116 cells as shown in Figure 1. There-
fore, GRK5, rather than TIG1 protein, may play a major
role in the suppression of PGE2-stimulated HCT116 cell
growth.
There are several study limitations that warrant con-
sideration. Firstly, HCT116 cells harbor a somatic b-
catenin mutation rendering it resistant to GSK-3b-
dependent phosphorylation and degradation [32,33].
Nevertheless, PGE2-mediated nuclear accumulation of
b-catenin was observed in the present study, which was
altered upon TIG1 expression. Secondly, although it is
well known that the COX-2/PGE2/EP2 response path-
way plays a critical role in colorectal cancer progression
Figure 5 Effects of TIG1 isoforms on cAMP levels. Control (Ctrl),
TIG1A and TIG1B stable HCT116 cells were incubated with 5 nM
MFP for 24 h, serum starved for 16 h, and then treated with or
without PGE2 (10 nM) for 5 min. Levels of cAMP were measured
using an enzyme immunoassay. Representative results from
triplicate samples were expressed as mean ± SD. *, P < 0.05; **, P <
0.01.
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[16], HCT116 cells are COX-negative and, therefore, do
not produce endogenous PGE2 [39]. Thus, the effects of
TIG1 expression on cell proliferation and b-catenin sub-
cellular localization and transactivation by endogenously
produced PGE2 could not be assessed. However, lack of
endogenous PGE2 production by HCT116 cells provides
the advantage of analyzing the effect of exogenous PGE2
alone. Using SW620 cells that express COX-2 and wild
type b-catenin, we observed that cellular growth stimu-
lated by exogenous PGE2 was inhibited by both TIG1
isoforms (additional file 1). In the absence of PGE2
addition, both TIG1 isoforms inhibited the growth of
SW620 cells that can produce PGE2 [11]. Similarly,
basal cell growth in TIG1A-expressing SW620 stable
cells incubated in serum-free medium without PGE2
treatment was significantly lower than that of control
stable cells (additional file 1). Considering that TIG1-
mediated inhibition of PGE2-stimulated TOPFLASH
and CREB reporter activities and nuclear b-catenin
accumulation was suppressed by GRK5 siRNAs in
HCT116 cells, TIG1 may therefore inhibit SW620 cell
growth through inhibition of endogenous PGE2 signal-
ing. Finally, TIG1 is a putative tumor suppressor that is
frequently hypermethylated in several cancer tissues;
hypermethylation is strongly associated with loss of
TIG1 gene expression [8,9]. Loss of TIG1 expression
[14] and an increase in COX-2 expression [40] are
related to the progression of colorectal cancer. Future
analysis in reactivation of TIG1 expression in TIG1
hypermethylated cells that do not harbor b-catenin
mutation, knockdown of TIG1 expression in high TIG1-
expressing cells as well as analysis of the clinical signifi-
cance between TIG1 and COX-2 expression may pro-
vide further information on the physiological
significance of TIG1 on PGE2-mediated colorectal
carcinogenesis.
Conclusions
In conclusion, both TIG1A and TIG1B suppressed
PGE2-stimulated colon cancer cell proliferation, b-cate-
nin nuclear localization, b-catenin/TCF transactivation,
and cAMP/CREB signaling through expression of GRK5.
The suppression of b-catenin/TCF transactivation and
b-catenin nuclear localization was mediated through
GRK5. The results suggest an inhibitory role of TIG1 on
PGE2-mediated colorectal carcinogenesis at least in part,
through upregulation of GRK5 expression.
Additional material
Additional file 1: Effects of TIG1A and TIG1B expression on PGE2-
induced SW620 cell growth. Control, TIG1A and TIG1B inducible stable
cells established from SW620 colon cancer cells using the GeneSwitch
system [11] were plated overnight, serum starved for 16 h and then
incubated in serum- free medium in the absence or presence of PGE2
(10 nM) for 48 to 72 h. MFP was present during serum starvation and
PGE2 addition. Cell growth was determined using the WST-1 cell
proliferation assay. *, P < 0.05.
Additional file 2: GRK5 suppressed PGE2-stimulated TOPFLESH and
CREB reporter activities in EP2-transfected HCT116 cells. HCT116
cells were transiently transfected with 250 ng of TOPFLASH or CREB
reporter plasmid along with 100 ng of indicated control vector or EP2
TrucClone™™ cDNA (PTGER2, OriGene Technologies, Inc. Rockville, MD,
USA) and 50 to 150 ng of GRK5 expression vectors for 24 h. Cells were
serum starved for 16 h and then incubated with or without 10 nM PGE2
for 24 h. Reporter activities were measured as described in the Materials
and Methods. Representative results were expressed as means ± SD from
triplicate samples. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Additional file 3: TIG1 and GRK5 siRNAs increased PGE2-stimulated
nuclear b-catenin accumulation in TIG1A-expressing cells. Control or
TIG1A stable cells were transfected with the indicated siRNA and then
incubated with 5 nM MFP for 24 h. Cells were serum starved for 16 h
and then stimulated with 10 nM PGE2 for 30 min. MFP was present
during serum starvation and PGE2 treatment. b-catenin localization
(green) and nuclei (blue) were analyzed using a laser scanning confocal
microscope. Bars, 10 μm. Arrows indicate cells expressing nuclear b-
catenin.
Additional file 4: Effects of PGE2 on nuclear b-catenin localization
in control siRNA transfected TIG1A-expressing cells. TIG1A stable
cells were transfected with control siRNA and then incubated with 5 nM
MFP for 24 h, serum starved for 16 h, and treated with or without 10 nM
PGE2 for 30 min. MFP was present during serum starvation and PGE2
treatment. Nuclear and cytosolic fractions were prepared, and subcellular
distribution of nuclear and cytosolic b-catenin was determined by
Western blot analysis. Normalization in the levels of nuclear and cytosolic
b-catenin was described in the Materials and Methods, and relative levels
of nuclear b-catenin in cells without PGE2-treatment was designated as
1.0.
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